Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.

Plain-language summary

This observational study examined the biological factors behind the withdrawal syndrome that can occur when tyrosine kinase inhibitor (TKI) drugs are stopped in patients with chronic myeloid leukemia (CML). Adult CML patients who were candidates for stopping TKI treatment were included. The study had no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University Hospital, Caen

Start date

4/23/2019

Estimated completion

3/16/2023

Countries

France

Related genes

Locations

• Caen, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Adult CML patient candidate for TKI discontinuation.
* Performans status : 0-2
* Patient provided with information

Exclusion Criteria:

* Patient unable to fulfill the questionnaires
* Patient suffering from demantia
* Patient treated with any cytokine antagonist